CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 73 enrolled
Drug / intervention
Imatinib Mesylatedrug
Likely dose
Imatinib Mesylate 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00510653
NCT00510653Phase 2Completed
CompareCT.gov

A Phase II Study of Gleevec in Patients With Recurrent Platinum-Resistant, Taxane-Resistant Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

M.D. Anderson Cancer Center·interventional·Posted Aug 2, 2007·Updated Aug 23, 2013

In Brief

A Phase 2 clinical trial evaluating Imatinib Mesylate for Ovarian Cancer. Completed, enrolled 73 participants across 1 site.

Detailed Summary

Primary Objectives: 1. To determine the efficacy of Gleevec in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer whose tumor expresses either c-KIT, platelet-derived growth factor receptor (PDGRF), or ABL. 2. To determine the nature and degree of toxicity of Gleevec in this cohort of patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2, 2007
Enrollment StartMar 1, 2002
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 18.9 years ago

Interventions

Imatinib Mesylatedrug

600 mg by mouth daily for 6 Weeks